A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma

Summary

This is a Phase 1b/2, multicenter, open-label, study of prizloncabtagene autoleucel (prizlo-cel), an autologous dual targeting chimeric antigen receptor (CAR) T-cell therapy targeting both cluster of differentiation (CD) CD20 and CD19, for the treatment of adult participants with relapsed or refractory (r/r) B-Cell non-Hodgkin lymphoma (B-NHL) or frontline high-risk diffuse large B-cell lymphoma (DLBCL).

Timeline

Start

2022-08-12

Primary completion

2028-12-29

Completion

2041-07-30

Drugs

Indications